Trial Profile
Phase I/II Randomized, Double Blind, Placebo Controlled, Dose Escalation, Safety and Pharmacokinetics Study in VLBW Neonates, a Human Chimeric Anti-Staphylococcal Monoclonal Antibody for the Prevention of S. Epidermidis Infection
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Pagibaximab (Primary)
- Indications Sepsis; Staphylococcal infections
- Focus Adverse reactions
- Sponsors Biosynexus
- 05 Nov 2010 New trial record.